Inhibitors of Protein Kinases and Protein Phosphates
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both ba...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Berlin, Heidelberg :
Springer Berlin Heidelberg,
2005.
|
| Σειρά: | Handbook of Experimental Pharmacology,
167 |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems
- General Aspects of PKs Inhibition
- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions
- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases
- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3
- Pharmacological Potential of p38 MAPK Inhibitors
- Inhibitors of PKA and Related Protein Kinases
- Inhibitors of Protein Kinase CK2: Structural Aspects
- Aminoglycoside Kinases and Antibiotic Resistance
- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases
- Protein Tyrosine Phosphatases as Therapeutic Targets
- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors
- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target
- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity
- Inhibitors in Clinical Use or Advanced Clinical Trials
- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus
- Targeted Therapy with Imatinib: An Exception or a Rule?
- Clinical Aspects of Imatinib Therapy
- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy
- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.
